Abstract 13464: Pentraxin 3 is Uninfluenced by High Doses of Concentrated Omega-3 Fatty Acids Administered for 12 Months Following an Acute Myocardial Infarction

Background: Treatment with n-3 fatty acids has shown to improve outcome in patients with myocardial infarction (MI). However, the pathophysiological mechanisms of their beneficial effect are still being debated. Although anti-inflammatory mechanisms have been postulated, their influence on high sensitivity C-reactive protein (hs-CRP) is controversial. Hs-CRP belongs to the pentraxin family, so also does the recently identified long pentraxin 3 (PTX3) which has been found to reflect the inflammatory state of the vasculature and has been shown to predict outcome in MI patients. The aim of the present analysis was to assess the effect of long-term treatment with high doses of omega-3 fatty acids on circulating plasma levels of PTX3. Methods: In the OFAMI study (ClinicalTrials.gov; NCT01422317), 300 MI patients were randomised to blindly receive 4 gelatine capsules of omega-3 in a concentrated ethylester form, each capsule containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Omaco...